A meta-analysis on effects of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia

This meta-analysis of 10 studies involving 2659 patients shows that chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for relapsed/refractory B-cell acute lymphoblastic. The pooled analysis showed a high minimal residual disease-negative complete remission, with an overall event rate (ER) of 70%. The most effective was Anti-CD19 CAR T-cell therapy, with an ER of 74.75%. Significant adverse effects included cytokine release syndrome, neurotoxicity, and hematologic toxicities.